

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
Andrew Furness, MD, PhD	Faculty	<ol style="list-style-type: none"> 1. Achilles Therapeutics, GSK, Immunocore, Neogene 2. BMS, Eisai, Ipsen, Merck, Pfizer 3. Co-inventor of methods of identifying responders to cancer treatment (WO2019008375A1) 4. ESMO 	<ol style="list-style-type: none"> 1. Non-CE Consulting 2. Non-CE Speakers Bureau 3. Receipt of Intellectual Property Rights / Patent Holder 4. Travel/Meeting Attendance 	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Annika Fendler, PhD	Faculty, Planning Committee Member	No relevant financial disclosures	N/A	N/A
Arnaud Méjean, MD, PhD	Faculty	No relevant financial disclosures	N/A	N/A
Ashley Smeaton, MHA	TFF Staff	No relevant financial disclosures	N/A	N/A
Axel Bex, MD, PhD	Faculty	1. BMS, Ipsen, Pfizer, Roche	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Berit Eberhardt	Faculty	No relevant financial disclosures	N/A	N/A
Bernard Escudier, MD	Faculty	Ipsen, MSD, Oncorena	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
		Ipsen, MSD, Oncorena	2. Contract Research	it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Bradley Leibovich, MD	Faculty	No relevant financial disclosures	N/A	N/A
Brian Rini, MD	Faculty	<p>1. ADC Therapeutics, Adela, Aravive, Arcus, Arrowhead Pharmaceuticals, AstraZeneca, AVEO, BMS, Daiichi Sankyo, Dracen Pharmaceuticals, Dragonfly Therapeutics, Exelixis, Genentech, Gilead, HiberCell, Incyte, Janssen, Merck, Pfizer, Pionyr, POINT Biopharma, Stata Oncology, Surface Oncology, Tempus,</p> <p>2. Alkermes, Aravive, Arrowhead, Athenex, Aveo, BMS, Corvus, Debiopharm, Eisai, EUSA, Exelixis, GNE/Roche, HiberCell, Merck, Nikang Therapeutics, Pfizer, Surface Oncology</p>	<p>1. Contract Research to Institution</p> <p>2. Non-CE Consulting</p>	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Camillo Porta, MD	Faculty	<p>1. Angelini Pharma, Astra Zeneca, BMS, Eisai, Ipsen, MSD</p> <p>2. Angelini Pharma, BMS, Eisai, Ipsen, MSD</p> <p>3. Eisai, MSD</p>	<p>1. Non-CE Consulting</p> <p>2. Non-CE Speakers Bureau</p> <p>3. Protocol Steering Committee Member</p>	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
Charlotte Spencer, MBBS	Faculty	No relevant financial disclosures	N/A	N/A
Christian Beisland, MD PhD	Faculty	No relevant financial disclosures	N/A	N/A
Cristina Suárez Rodríguez, MD, PhD	Faculty, Planning Committee Member	<ol style="list-style-type: none"> 1. Astellas, Bayer, BMS, Ipsen, MSD, Pfizer, Roche, Sanofi 2. Astellas, BMS, Ipsen, Pfizer, Roche 3. Ipsen 	<ol style="list-style-type: none"> 1. Non-CE Consulting 2. Non-CE Speakers Bureau 3. Contract Research 	<p>All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee members.</p> <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Daniel Heng, MD, MPH, FRCPC	Faculty	<ol style="list-style-type: none"> 1. BMS, Ipsen, Eisai, Exelixis, Merck, Novartis, Pfizer 2. BMS, Ipsen, Eisai, Exelixis, Merck, Novartis, Pfizer 	<ol style="list-style-type: none"> 1. Non-CE Consulting 2. Contract Research 	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
David Braun, MD, PhD	Faculty	<ol style="list-style-type: none"> 1. AVEO, Exelixis 2. AbbVie, Accolade 2nd MD, Adnovate Strategies, Aptitude Health, ASCO Post/Harborside, Cancer Expert Now, CancerNetwork, Catenion, Cello Health BioConsulting, Compugen, DLA Piper, Elephas, Haymarket, 	<ol style="list-style-type: none"> 1. Advisory Board 2. Non-CE Consulting 	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
		<p>Link Cell Therapies, Medical Network, MDedge, Merck, OncLive, Pfizer, PWW Consulting, Scholar Rock, Targeted Oncology</p> <p>3. AstraZeneca, Exelixis</p> <p>4. Fortress Biotech</p>	<p>3. Contract Research</p> <p>4. Stock options in publicly traded company</p>	
David Cella, PhD	Faculty	<p>1. AbbVie, Black Diamond, BMS, Disc Medicine, Exact Sciences, Ipsen, Merck, Novartis, Pfizer, Takeda</p> <p>2. BMS, Merck, Novartis, Pfizer</p> <p>3. President, FACIT.org</p>	<p>1. Non-CE Consulting</p> <p>2. Contract Research</p> <p>3. Receipt of Intellectual Property Rights / Patent Holder</p>	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
David McDermott, MD	Faculty	1. Cullinan Oncology	1. Advisory Board	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Dena Battle	Faculty	No relevant financial disclosures	N/A	N/A
Enrique Trilla Herrera, MD, PhD	Faculty	No relevant financial disclosures	N/A	N/A

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
Eric Jonasch, MD, MS	Faculty	1. AbbVie, Arrowhead, Aravive, Aveo, BMS, Corvus, Exelixis, Merck, NiKang, Novartis, ProfoundBio, Telix 2. Aveo, DAVA, Eisai, Exelixis, GSK, Ipsen, Merck, NiKang, Novartis, Takeda, Telix	1. Research Funding 2. Honoraria	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Ferran Algaba Arrea, MD, PhD	Faculty	No relevant financial disclosures	N/A	N/A
Gretchen Vaughan, BBA	KCA Staff	No relevant financial disclosures	N/A	N/A
Gabriel Malouf, MD, PhD	Planning Committee Member	1. BMS, Eisai, Ipsen, MSD 2. MSD AVENIR	1. Non-CE Consulting 2. Contract Research	All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee members.
Guillermo De Velasco, MD, PhD	Faculty	1. Astellas, BMS, Ipsen, Janssen 2. Astellas, BMS, Bayer, Ipsen, Merck, MSD, Janssen, Pfizer, Roche	1. Non-CE Consulting 2. Non-CE Speakers Bureau	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Heather Tarbox, MPH	TFF Staff	No relevant financial disclosures	N/A	N/A
Ignacio Duran, MD, PhD	Faculty, Planning Committee Member	1. Astellas Pharma, Bayer, Bristol Myers Squibb, EUSA Pharma, Gilead, Ipsen, Janssen, MSD, Roche-Genentech, Novartis	1. Honoraria for lectures, presentations, educational events.	All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee members.

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
		2. Astellas Pharma, Bayer, Bristol Myers Squibb, Debio Pharma, Eisai, EUSA Pharma, Ipsen, MSD, Novartis, Pharmacyclics, Roche-Genentech	2. Compensated Advisory Boards	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Jeanette Stensgaard, MBA, CMP	KCA Staff	No relevant financial disclosures	N/A	N/A
James Brugarolas, MD, PhD	Faculty	1. Telix 2. Patent NO US 11,576,889 B2	1. Non-CE Consulting 2. Receipt of Intellectual Property Rights / Patent Holder	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Jean-Christophe Bernhard, MD, PhD	Faculty	No relevant financial disclosures	N/A	N/A
Juan Carlos Julián Mauro	Faculty	No relevant financial disclosures	N/A	N/A
Kate Young, MBBS, MA, MD(Res.), MRCP	Faculty	1. BMS, Eisai, Ipsen 2. AVEO Pharmaceuticals, Eisai, Ultimovacs, NIHR RM/ICR Biomedical Research Centre for Cancer, RMP Cancer alliance, Melanoma Focus	1. Payment for teaching/promotional meetings 2. Institutional research support	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Kristen Brady	TFF Staff	No relevant financial disclosures	N/A	N/A
Lars Lund, MD, DMSci	Faculty, Planning Committee Member	No relevant financial disclosures	N/A	N/A

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
Laura Bukavina, MD, MPH	Faculty	1. Charite, UroGen Pharma, Associate Editor of European Urology, Editorial Board Member Urology Times 2. Bladder Cancer Advocacy Network and AUA	1. Non-CE Consulting 2. Funding	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Laurence Albiges, MD, PhD	Faculty	1. Astellas, AMGEN, BMS, Eisai, Ipsen, Janssen, Merck, MSD, Novartis, Pfizer, Roche	1. Non-CE Consulting	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Lisa Pickering, MD	Faculty, Planning Committee Member	1. Bristol Myers Squibb, Eisai, EUSA, Ipsen, MSD Biomedical, and Pfizer	1. Non-CE Speakers Bureau	All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee members. Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Lisa Wintner, PhD	Faculty	No relevant financial disclosures	N/A	N/A
Mamta Parikh, MD, MS	Faculty	1. Bristol Myers Squibb, Myovant, Natera, Pfizer, Sanofi	1. Non-CE Consulting	The following relationships ended: <ul style="list-style-type: none"> ▪ Bristol Myers Squibb: December 2022 ▪ Myovant: June 2023 ▪ Natera: September 2022 ▪ Pfizer: June 2023

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
				Sanofi: June 2023 Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Manuela Schmidinger, MD	Faculty	1. AstraZeneca, BMS, Eisai, Exelixis, Ipsen, Merck, MSD, Pfizer	1. Honoraria or Advisory Boards	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Martin Voss, MD	Faculty	1. AstraZeneca, Merck, Nikang, 2. Affimed, Alexion, Aveo, BMS, Calithera, Chengdu, Corvus, Eisai, Exelixis, Genetech, Natera, Novartis, Oncorena, Pfizer	1. Non-CE Consulting 2. Contract Research	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Maxine Tran, MD, PhD, FRCS, MBBS	Faculty	1. GSK 2. AngioDynamics, Boston Scientific Inc, MSD	1. Contract Research 2. Speaker & consultancy fees and honorarium	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Michael Staehler, MD, PhD	Faculty, Planning Committee Member	1. Aveo, Bayer, BMS, Eisai, Exelixis, GlaxoSmithKline, Immatics, Ipsen, Novartis, Pfizer, Roche/Genentech, Willex	1. Research Funding	All final planning decisions concerning content, learning objectives, and evaluation questions were made by the non-conflicted Planning Committee members.

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
		<p>2. Apogepha, Astellas, Aveo, Bayer, BMS, EUSA Pharma, Eisai, Exelixis, GlaxoSmithKline, Ipsen, Janssen, MSD, Novartis, Oncorena, Pelloton, Pfizer, Roche</p> <p>3. Apogepha, Astellas, Aveo, Bayer, BMS, GlaxoSmithKline, Eisai, EUSA Pharma, Exelixis, Ipsen, MSD, Novartis, Pelloton, Pfizer</p>	<p>2. Non-CE Consulting</p> <p>3. Honoraria</p>	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Rana McKay, MD	Faculty	<p>1. Ambrx, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Caris, Dendreon, Eisai, Exelixis, Gilead, Johnson & Johnson, Lilly, Merck, Myovant, Novartis, Pfizer, Sanofi, SeaGen, Sorrento Therapeutics, Telix, and Tempus</p> <p>2. AstraZeneca, Bayer, Bristol Myers Squibb, Exelixis, Oncternal, and Tempus</p>	<p>1. Non-CE Consulting</p> <p>2. Institutional Grant / Research Support</p>	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Raquibul Hannan, MD, PhD	Faculty	No relevant financial disclosures	N/A	N/A
Samra Turajlic, MBBS, PhD	Faculty	No relevant financial disclosures	N/A	N/A
Salvatore La Rosa, PhD	Faculty, KCA Staff	No relevant financial disclosures	N/A	N/A
Sarah Psutka, MD, MS	Faculty	1. Janssen	1. Contract Research	<p>The following relationships ended:</p> <ul style="list-style-type: none"> ▪ Merck: August 2021

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
		2. Merck 3. Bladder Cancer Advocacy Network, National Institute on Aging 4. <i>Bladder Cancer, European Urology</i> 5. Merck, ImmunityBio, Janssen	2. Non-CE Consulting 3. Research Funding 4. Editorial boards 5. Scientific Advisory Board	<ul style="list-style-type: none"> ▪ ImmunityBio: prior to April 2023 Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Sylvie Negrier, MD, PhD	Faculty	1. Ipsen, Pfizer 2. BMS, Eisai, Ipsen, MSD, Pfizer	1. Contract Research to Institution 2. Participation in sponsored scientific events	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Theodore Bruno, MD, FACEHP	TFF Staff	No relevant financial disclosures	N/A	N/A
Thomas Powles, MD, MBBS, MRCP	Faculty	1. Astellas, AstraZeneca, BMS GmbH & Co., Eisai, Exelixis, Incyte, Ipsen, Janssen, Johnson & Johnson, Mashup Ltd., Merck, Merck Serono, Novartis, Pfizer, Roche Laboratories, Seattle Genetics 2. Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Mashup Ltd., Merck,	1. Honoraria 2. Consulting or Advisory Role	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
		<p>Merck Serono, MSD, Novartis, Pfizer, Roche, Seattle Genetics</p> <p>3. Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck Serono, MSD, Novartis, Pfizer, Roche, Seattle Genetics</p> <p>4. AstraZeneca, MSD, Pfizer</p>	<p>3. Research Funding</p> <p>4. Travel, Accommodations, Expenses</p>	
Ulka Vaishampayan, MBBS	Faculty	<p>1. BMS Consulting, Merck</p> <p>2. Alkermes, Aveo, Bayer, BMS, Exelixis, Novartis, Pfizer</p> <p>3. Astellas, Bayer, Exelixis</p>	<p>1. Contract Research</p> <p>2. Non-CE Consulting</p> <p>3. Non-CE Speakers Bureau</p>	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.
Viktor Grunwald, MD, PhD	Faculty	<p>1. Amgen, Astellas, AstraZeneca, BMS, Eisai, Gilead, Ipsen, Janssen-Cilag, Merck Serono, MSD, Novartis, Pfizer</p> <p>2. Apogepha, BMS, Cureteq, Debiopharm, Eisai, Merck Serono, MSD, Oncorena, PCI Biotech, Pfizer, Roche, Synthekine</p>	<p>1. Invited Speaker</p> <p>2. Advisory Board</p>	Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
		<p>3. AstraZeneca, BMS, MSD</p> <p>4. BMS, Eisai, Ipsen, Novartis</p> <p>5. BMS, Ipsen, MSD, Pfizer</p>	<p>3. Stock options in publicly traded companies</p> <p>4. Steering Committee Member</p> <p>5. Institutional Research Grant</p>	
Xavier Maldonado, MD, PhD	Faculty	1. Bayer	1. Attended N3XT (Bayer meeting)	<p>The relationship with Bayer ended in February 2024.</p> <p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>
Yüksel Ürün, MD	Faculty	<p>1. Turkish Oncology Group</p> <p>2. Abdi-İbrahim, Astellas, AstraZeneca, Bristol Myers-Squibb, Eczacıbaşı, Genİlaç, Gilead, Janssen, Merck, MSD, Novartis, Pfizer, Roche</p> <p>3. Abdi-İbrahim, Astellas, Bristol Myers-Squibb, Eczacıbaşı, Genİlaç,</p>	<p>1. Research funding (Institutional and personal)</p> <p>2. Advisory Board</p> <p>3. Consultancy or Honoraria</p>	<p>Content was reviewed by a non-conflicted member of the planning committee to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning.</p>

2024 IKCS: Europe – Disclosures

Name	Role in Activity	Name of Commercial Entity	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest appropriate to the role(s) in the activity
		Gilead, Janssen, Merck, Novartis, Pfizer, Roche		
Zayd Tippu, MD	Faculty	No relevant financial disclosures	N/A	N/A